With the oral diabetes drugs market at Rs 13,000 crore and growing, a key diabetes medicine Sitagliptin going off patent means a sweet spot for all. How does the billion-dollar pharma industry see an opportunity in a market with the highest number of diabetes patients in the world. Host Kiran Somvanshi chats with Nithya Balasubramanian, Director at AB Bernstein, Sheetal Sapele, Marketing President of All Indian Origin Chemists & Distributors, and Vikas Dandekar, Editor - Pharma at ET Prime.
Credits: CNBC-TV18